Neoplasms

Nervous System Diseases

All Conditions

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Patients with diagnosis of brain cancer at any stage

Tumour markers testing

Michael Weller, MD

The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to:

* Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor;
* Identify or validate new molecularly defined subgroups of tumors;
* Investigate the prevalence of novel biomarkers to plan future clinical trials;
* Enable exploratory/future research;
* Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;

FFPE blocks of tumour tissue Blood samples

SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access

Screening Platform of EORTC for Clinical Trials Access in Brain Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Digestive System Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Tumour markers testing in patients with advanced or metastatic colo-rectal cancer

Tumour markers testing in patients advanced or metastatic colo-rectal cancer.

Gunnar Folprecht, MD

Sabine Tejpar, MD, PhD

Daniela Aust, MD

The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.

Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.

A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.

The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.

Screening Platform for Clinical Trials in Advanced Colorectal Cancer

Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer "SPECTAcolor"

Five basic tumour markers will be tested: Kras, nras, braf, MSI and PKI3

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access	NCT02307604	Brain Neoplasms	Tumour markers ...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Screening Platform for Clinical Trials in Advanced Colorectal Cancer	NCT01723969	Colorectal Canc... Advanced Colore...	Tumour markers ...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access	NCT02307604	Brain Neoplasms	Tumour markers ...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access	NCT02307604	Brain Neoplasms	Tumour markers ...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Screening Platform for Clinical Trials in Advanced Colorectal Cancer	NCT01723969	Colorectal Canc... Advanced Colore...	Tumour markers ...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC

Spots Global Cancer Trial Database for tumour markers testing